



Media Contact
Dan McFadden
dmcfadden@oculusis.com
(425) 836-3103

OCULUS INNOVATIVE SCIENCES FILES 510(K) WITH FDA FOR APPROVAL OF MICROCYN™ AS WOUND CARE DRESSING

Approval by FDA would permit the use of Microcyn™ in moistening and lubricating of absorbent dressings for traumatic wounds.

PETALUMA, CA-- (May 14, 2004)—Oculus Innovative Sciences announced today that the company has filed its 510(k) submission with the Food and Drug Administration for approval of the company's revolutionary Microcyn™ for moistening and lubrication of absorbent wound dressings in use on traumatic wounds, cuts, abrasions and minor burns. This is the first FDA submission for Microcyn technology in the United States.

The company's Microcyn technology has received a great deal of attention within the worldwide medical industry due to its effectiveness and friendly nature. In vivo tests performed to date confirm that Microcyn does not cause skin and eye irritation; is non-flammable, biodegradable and environmentally friendly.

Microcyn technology has received CE approval under the European Medical Device Directive 93/42/EEC as well approval for treatment of wounds and ulcers in Mexico.

"With the initial focus to commercialize Microcyn in Europe and Latin America," said Hoji Alimi, who founded the company in 1999, "Oculus is now turning its attention to the U.S. Food and Drug Administration and a successful first 510K application. We look forward to entering the U.S. market with such an innovative technology."

About Oculus

Oculus Innovative Sciences, headquartered in Petaluma, California, is pioneering innovative life sciences and disruptive technologies that globally re-define the disinfectant and antiseptic markets. The company has employees and operations in Mexico, Europe and the U.S. and includes two wholly owned subsidiaries, Oculus Technologies of Mexico, S.A. de C.V., and Oculus Innovative Sciences Netherlands B.V. Please visit us at www.oculusis.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. These forward-looking statements relate to, among other things, plans and timing for the introduction of our products, statements about future market conditions, supply and demand conditions, revenues, gross margins, operating expenses, profits and other expectations, intentions and plans contained in this press release that are not historical fact. Our expectations as expressed in this press release depend upon our ability to develop, manufacture and supply products that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in the health sciences market. In light of the many risks and uncertainties surrounding this market, you should understand that we cannot assure you that the forward-looking statements contained in this press release will be realized.

Disclaimer

This release concerns a use that has not been approved or cleared by the Food and Drug Administration or the Environmental Protection Agency.